抗VEGF (VG1)抗体 | Anti-VEGF (VG1) Antibody

• 価格
• Image
• Background

価格

目次に戻る

Image

	Western Blot: VEGF Antibody (VG1) [NB100-664] - HUVEC and 293T Cells tested at 1:1000. Image provided by verified customer review.
	Immunohistochemistry-Paraffin: VEGF Antibody (VG1) [NB100-664] - IHC analysis of a formalin-fixed paraffin embedded human angiosarcoma tissue section using VEGF antibody (clone VG1). The endothelial cells of the blood vessels and most of the cancer cells showed strong positivity for VEGF protein.
	Immunocytochemistry/Immunofluorescence: VEGF Antibody (VG1) [NB100-664] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-VEGF (VG1) [NB100-664] at a 1:200 dilution overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.
	Flow Cytometry: VEGF Antibody (VG1) [NB100-664] - Analysis of PerCP conjugate of NB100-664. An intracellular stain was performed on HUVEC cells with VEGF (VG1) antibody NB100-664PCP (blue) and a matched isotype control NBP2-27287PCP (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% s
	Western Blot: VEGF Antibody (VG1) [NB100-664] - Western blot analysis of VEGF in human kidney protein using NB100-664.
	Flow Cytometry: VEGF Antibody (VG1) [NB100-664] - An intracellular stain was performed on U-937 cells with VEGF Antibody (VG1) NB100-664 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse F(ab)2 IgG (H+L) PE-conjugated Antibody (R&D Systems, F0102B).
	Immunocytochemistry/Immunofluorescence: VEGF Antibody (VG1) [NB100-664] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with VEGF (VG1) NB100-664 at a 1:200 dilution overnight at 4 degrees Celsius and detected with Dylight 488 (Green). Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were detected with DAPI (Blue). Cells were imaged using a 40X objective.
	Flow Cytometry: VEGF Antibody (VG1) [NB100-664] - An intracellular stain was performed on U-937 cells with VEGF Antibody (VG1)NB100-664F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.

目次に戻る

Background

VEGF (vascular endothelial growth factor) is a homodimeric, disulfide-linked glycoprotein growth factor that plays a critical role in angiogenesis, vasculogenesis and endothelial cell growth through induction of endothelial cell proliferation and blood vessels permeabilization, cell migration promotion as well as inhibition of apoptosis. VEGF can bind to FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Its isoforms VEGF189, VEGF165 and VEGF121 are widely expressed, whereas, other isoforms VEGF206 and VEGF145 are not very common. The basic isoform VEGF189 is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. VEGF bind to three tyrosine-kinase receptors, VEGFR-1, VEGFR-2 and VEGFR-3 which are expressed almost exclusively in endothelial cells. VEGFR-2 is the main angiogenic signal transducer for VEGF, while VEGFR-3 is specific for VEGF-C/-D (may gain VEGFR-2 binding ability via proteolytic processing) and is essential for lymphangiogenic signaling. VEGF is regulated by growth factors, cytokines, gonadotropins, nitric oxide, hypoxia, hypoglycemia and oncogenic mutations. Defects in VEGFA are linked to MVCD1 (microvascular complications of diabetes type 1) and VEGF polymorphisms are associated with susceptibility to multiple cancers, e.g., glioma, HCC, ovarian, bladder, prostate, breast cancer etc.

目次に戻る